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OBJECTIVES This study was designed to compare different proposed methods of assessing adherence with
angiotensin-converting enzyme (ACE) inhibitor (ACEI) therapy in chronic heart failure.
BACKGROUND The use of ACEIs in chronic heart failure gives us a unique opportunity to assess a patient’s
adherence by measuring whether the expected biochemical effect of an ACEI is present in the
patient’s bloodstream. In fact, there are several different ways of assessing ACE in vivo: these
are serum ACE activity itself, plasma N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), urine
AcSDKP, plasma angiotensin I (AI), plasma angiotensin II (AII), or the AII/AI ratio.
METHODS Patients with chronic heart failure (n 5 39) were randomized to regimens of ACEI
nonadherence for one week, ACEI adherence for one week or two versions of partial
adherence for one week, after which the above six tests were performed.
RESULTS All six tests significantly distinguished between full nonadherence for one week and full or
partial adherence. Only plasma AcSDKP produced a significantly different result between
partial adherence and either full adherence or full nonadherence for one week. In terms of
their ability to distinguish full nonadherence from full adherence, plasma AcSDKP was 89%
sensitive and 100% specific with an area under its ROC of 0.95. Corresponding figures for
urine AcSDKP were 92%, 97% and 0.95 and for serum ACE they were 86%, 95% and 0.90.
CONCLUSIONS All six tests distinguished full nonadherence from all other forms of adherence. The rank
order of performance was plasma AcSDKP, urine AcSDKP, serum ACE, AII/AI ratio and
plasma AII followed by plasma AI. (J Am Coll Cardiol 1999;34:2072–7) © 1999 by the
American College of Cardiology
In chronic heart failure, the main therapeutic advance in the
last 20 years has been the advent of angiotensin-converting
enzyme (ACE) inhibitors (ACEIs) that improve mortality,
morbidity and hospitalization rates (1). For an individual
patient to gain maximum benefit from ACEI therapy, it is
obviously important to adhere to this therapy. Yet most
patients with chronic heart failure are elderly and receiving
multiple drug therapy, which are both factors known to
enhance nonadherence. Indeed, many studies do show that
nonadherence with drug therapy is common in patients with
chronic heart failure (2). In one study, elderly patients with
chronic heart failure were estimated to take none of their
therapy (digoxin) for an average of 111 d/yr (3). Impor-
tantly, in that study, there was a very large interindividual
variability in adherence between different patients. The
consequences of this nonadherence could be important since
nonadherence is commonly present in hospitalized patients
and improving adherence appears to reduce recurrent hos-
pitalizations (2,4,5).
Identifying which patients are nonadherent with ACEI
therapy may be possible by measuring in the patient’s
bloodstream or urine whether the ACE enzyme is inhibited.
There are, in fact, several ways to do this. First, one can
measure serum ACE activity itself, which we have found to
be a very sensitive indicator of whether an ACEI has been
recently swallowed (6,7). Secondly, in 1997, Azizi et al. (8)
suggested that the measurement of N-acetyl-seryl-aspartyl-
lysl-proline (AcSDKP) is a better marker of adherence with
ACE inhibition (8). This is an endogenous peptide that is
metabolized by ACE, and ACE inhibition has been shown
to induce AcSDKP in both plasma and urine (8). Thirdly,
the ratio of angiotensin II (AII) to angiotensin I (AI) is
probably the best index of whether ACE is inhibited in vivo,
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but the method to measure this is so cumbersome, that it is
hard to imagine that this method could become a routine
test to assess adherence with therapy unless it strongly
outperformed the other methods (9). The main aim of our
study was to perform a head-to-head comparison of these
three biochemical techniques in their ability to detect
nonadherence with ACEI therapy.
The problem of adherence is complex, however, because
patients do not necessarily fall into the category of being
either totally adherent or totally nonadherent. There are
many different versions of partial compliance. The second
aim of our study was therefore to compare the tests
described above not only in the situation of full adherence
and full nonadherence but also with various patterns of
partial compliance.
Therefore we have not only compared three different
ways of measuring adherence with therapy but have done so
during various patterns of partial and full adherence.
METHODS
Patient selection and protocol. Thirty-nine patients with
chronic heart failure were recruited. The diagnosis of
chronic heart failure was based on either echocardiographic
or radionuclide evidence of LV systolic dysfunction (LVEF
,45%). The study protocol was approved by our local
research and ethics committee and written informed con-
sent was obtained from all patients. All patients were
receiving regular stable therapy with furosemide and lisin-
opril for at least two months before recruitment.
Each patient underwent the four seven-day treatment
phases described below in a randomized fashion, inter-
spersed with four weeks of their “normal” furosemide/
lisinopril therapy. The four treatment phases were as fol-
lows: 1) full nonadherence: placebo therapy was substituted
for their lisinopril for seven days (10); all other therapy was
unchanged; 2) full adherence: lisinopril therapy (usual dose)
was continued for seven days; all other therapy was un-
changed; 3) clinic day adherence: placebo therapy was
substituted for their lisinopril for six days followed by
lisinopril (usual dose) on day 7 only; all other therapy was
unchanged; and 4) half adherence: placebo therapy was
substituted for their lisinopril on days 1, 3, 5 and 7; lisinopril
therapy (usual dose) was taken on days 2, 4 and 6; and all
other therapy was unchanged.
The patients attended on day 7 of each treatment period,
at 3 to 6 h after their morning dose and having collected a
24-h urine sample. At each visit, they lay in supine position
for 30 min, after which blood was taken for the measure-
ment of serum ACE activity, plasma AcSDKP, plasma AI
and plasma AII. The blood samples for AI and AII were
collected into tubes containing 20 mmol/L of a renin
inhibitor (H142) along with enalaprilat, neomycin, phenan-
throline and EDTA. These substances, especially the renin
inhibitor, were designed to prevent the in vitro generation of
AII from the excess AI that was inevitably present due to
the ACEI. All blood samples were collected on ice, centri-
fuged immediately at 4°C and the plasma or serum stored at
270°C prior to assaying them in batches.
Biochemical assays. Serum ACE activity was assayed by
monitoring the change in absorbance at 340 nm of the
hydrolysis of furylacrylolylphenylalanylglycylglycine
(FAPGG) to FAP and GG (Sigma-Aldrich Chemical
Company; Poole, Dorset GH12 4QH) on an analyzer
(Roche MIRA Analyser; Roche Diagnostic Systems; Wel-
wyn Garden City, Herts, AL7 3AY).
Plasma AI and AII were measured by Dr. J.J. Morton of
the Department of Medicine and Therapeutics, University
of Glasgow, using highly specific radioimmunoassays as
described in more detail previously (11). Plasma and urine
levels of AcSDKP were measured by a competitive enzyme
immunoassay by Dr. Ezan in Paris using the technique
described in more detail by those same workers (12,13).
Statistical analysis. Scattergrams were first constructed to
visualize the data. For each biochemical test in isolation,
two-way analysis of variance was then undertaken to see if
the test was able to differentiate between the various
patterns of adherence. Multiple comparisons were per-
formed by Duncan’s test for homogenous subsets. Since all
tests could readily distinguish between full nonadherence
and all three other patterns of adherence, the main com-
parison between the tests was to see how each test per-
formed in distinguishing full adherence from full nonadher-
ence. To compare tests in this regard, we constructed ROC
curves for each test and compared them. We also calculated
the sensitivity, specificity, positive predictive accuracy and
the negative predictive accuracy of each test as a way of
comparing the various tests.
RESULTS
Our patients were typical patients with chronic heart failure
(age 71 6 6 years taking 75 6 35 mg furosemide equivalents
and 13 6 6 mg lisinopril). There was no indication that the
subsequent hormonal results varied according to the dose of
furosemide or the dose of lisinopril.
Figure 1 shows how each measurement performed on an
individual basis. Analysis of variance was used to see how
each test compared across a range of different forms of
adherence. All tests were readily able to distinguish full
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ACEI 5 angiotensin-converting enzyme inhibitor
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adherence from full nonadherence. The two forms of partial
adherence look indistinguishable from each other for all
tests and they look similar to full adherence for all tests
except plasma AcSDKP, in which partial adherence appears
to produce values intermediate between full adherence and
full nonadherence. The analysis of variance shown in Table
1 confirms this impression, ie, for ACE, AII/AI ratio, AI
and AII, full nonadherence was significantly different from
full adherence, half adherence and from an ACEI on day 7
only, but there was no significant difference among the latter
three. However, for plasma AcSDKP, there was not only a
significant difference between full adherence and full non-
adherence, but each of them was also significantly different
from both forms of partial adherence. (Urine AcSDKP was
not tested in its ability to detect partial adherence because
the 24-h samples covered time periods when adherence was
changing in the partial adherence situations. All patients did
collect 24-h urine specimens on all treatment regimens so
that they remained blind to which drug regimen they were
receiving.)
To directly compare each test, we constructed ROC
curves to compare the ability of all six tests to distinguish
between full adherence and full nonadherence (Table 2).
The area under the ROC was high for all tests and the only
significant difference was between the very best (AcSDKP)
and the very worst (plasma AI). Table 3 shows the sensi-
tivity and specificity of each test and again all tests per-
formed well with a rank order of AcSDKP, (plasma and
urine equal) ACE, AII/AI, AII and then AI. In absolute
terms, both AcSDKP and ACE had sensitivities and
specificities .85% and areas under ROC curves .0.9,
which make both acceptable for clinical practice.
Figure 1. Scattergram of serum ACE activity (U/liter) plasma AcSDKP (pmol/ml), urine AcSDKP (nmol/liter), plasma AI (pmol/liter),
plasma AII (pmol/liter), and AII/AI ratio during different patterns of adherence with ACEI therapy.
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DISCUSSION
Our main conclusions are as follows. In general, all tests
performed fairly well with a rank order of AcSDKP, ACE,
AII/AI, AII and then AI. In particular, all tests above could
distinguish full adherence from full nonadherence. Only
AcSDKP could distinguish the two forms of partial adher-
ence from both full adherence and full nonadherence.
The placebo tablets appeared identical to the lisinopril
tablets, ie, this was a double dummy technique. From the
ethical point of view, the replacement of lisinopril by
placebo occurred only for a maximum of seven consecutive
days and for a total of 17 days over 16 weeks. In the study
of Pflugfelder et al. (10) in 1993, there was no clinical
worsening of heart failure until treatment with an ACEI
had been stopped for six weeks. We therefore believed that
our patients were at very little (or no) risk when their
lisinopril therapy was stopped for these brief periods.
It is widely recognized that nonadherence with therapy is
an important practical problem (14). It is also widely
appreciated that assessing adherence to therapy in the real
world is notoriously difficult and that no method for
assessing adherence will ever be perfect. Our proposal to
take a blood sample from an unsuspecting patient has the
major advantage that the patient is not alerted that his or
her adherence is being monitored.
Practical implications. It is fortunate that AI, AII and the
AII/AI ratio did not outperform AcSDKP or ACE, because
Table 1. A Comparison of Different Tests and How They Perform at Separating Various
Patterns of Compliance
Tests Mean Value
Serum ACE, U/liter
Full nonadherence 29.4
p , 0.001
Full adherence 13.1
Half adherence 16.3 0.072
ACEI day 7 13.7
Plasma AcSDKP, pmol/ml
Full nonadherence 1.3
p , 0.001
Full adherence 5.7 p , 0.001
p , 0.001
Half adherence 3.7
p 5 0.248
ACEI day 7 4.2
Plasma AI, pmol/liter
Full nonadherence 147
p , 0.001
Full adherence 586
Half adherence 508 p 5 0.411
ACEI day 7 524
Plasma AII, pmol/liter
Full nonadherence 25
p , 0.001
Full adherence 3.6
Half adherence 8.0 p 5 0.282
ACEI day 7 5.2
AII/AI ratio
Full nonadherence 0.291
p , 0.001
Full adherence 0.046
Half adherence 0.1475 p 5 0.139
ACEI day 7 0.057
Table 2. Area Under ROC Curves for Each Test to Compare
Full Adherence With Full Nonadherence*
Test Value
Serum ACE 0.90
Plasma AcSDKP 0.95
Urine AcSDKP 0.95
p , 0.05
Plasma AI 0.77
Plasma AII 0.85
AII/AI Ratio 0.89
*There were no statistically significant differences among the above tests (Wilcoxon)
except for the two extremes above, i.e., AcSDKP versus plasma AI.
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the former are so technically difficult to measure that there
are only three laboratories in Europe that can measure AII
in the presence of an ACEI. As to AcSDKP and ACE, the
former performs better because it can identify partial adher-
ence. However, the performance of ACE is still fairly good
and it does have the advantage that most routine hospital
laboratories already measure ACE as a diagnostic test for
sarcoidosis along with the fact that it is inexpensive and it
can easily be automated on standard analyzers. The choice
over whether to use AcSDKP or ACE in clinical practice
will therefore depend on local circumstances.
Consequences of nonadherence. What are the conse-
quences of nonadherence that might be preventable by
targeting adherence-enhancing strategies? First, nonadher-
ence probably leads to hospitalizations (2,4). Second, non-
adherence leads to AII reactivation, which is known to
produce a worse prognosis in terms of mortality and in
terms of progression of LV dysfunction (15).
Study limitations. Our study applies only to lisinopril as
the ACEI. It is uncertain how widely applicable these
findings would be to other ACEIs. One particular ACEI in
which serum ACE would not be a useful test is captopril
because it uniquely has poor affinity for ACE in vitro that
causes it to dissociate from ACE in a blood sample. This is
why serum ACE is not able to be used to assess adherence
when captopril is the prescribed ACEI. This specific prob-
lem with captopril does not appear to apply to the other
measures of adherence (16). The other limitation in our
study was that for ethical reasons, we switched patients to
the placebo regimen for only seven days, and it is possible
although unlikely that our biochemical measures had not
fully returned to their baseline values. This seems unlikely to
be a problem for serum ACE since serum ACE inhibition
falls to only 40% at 72 h after lisinopril, which means that
serum ACE inhibition is likely to be minimal by seven days
(17). Furthermore, in our study, serum ACE, plasma
AcSDKP and the AII/AI ratio were all in the expected
population range after seven days of placebo therapy. A final
limitation is that serum ACE was herein measured in
samples that had been stored frozen, and freezing the
samples is thought to cause a 20% increase in the absolute
values for ACE. Therefore, the absolute cutoff value that we
used in the present study for ACE may be a bit higher than
would be the case if ACE was measured on fresh samples in
routine practice. Our previous work with freshly assayed
samples for ACE suggests that this is indeed the case (7).
Future questions. Our study does not, in itself, answer all
detailed questions on the practical use of these tests. One
might think that the dose of the ACEI would be a factor in
interpreting the assay results, but in 1998, van Veldhuisen et
al. (18) found the same suppression of serum ACE with
three different ACEI doses. Another factor that might be
relevant to interpreting results is the patient’s ACE geno-
type but again at peak drug effect, serum ACE is only
3.6 U/L different between the II and DD genotype (19).
Furthermore, in normal clinical practice, one does not know
a patient’s genotype. The timing of the blood sample in
relation to the timing of drug ingestion might also be
important but with lisinopril, serum ACE suppression is
96% at 6 h and 80% at 24 h, which suggests that it might
not matter that much when in the 24 h period the blood
sample is taken since serum ACE suppression is fairly stable
over this time period (18). Therefore, although these issues
of detail ought to be formally addressed by future studies, it
seems unlikely that dose, timing and genotype will have any
major impact on the clinical utility of serum ACE as a
measure of adherence, although as yet, little is known about
these details and AcSDKP.
It is also worth emphasizing that the occasional high
ACE activity values were not laboratory errors since quality
control samples were run in all batches and long-term
analytical variation was always ,10%. Nevertheless, there
were a few outlying points. These could be because some
patients did not follow our instructions exactly, which again
emphasizes the difficulties involved in doing research on
adherence. However, any such problem would apply equally
to all tests under comparison and we were anxious not to
exclude any data. However, it is possible that clearly
interpretable values will not be obtained in all patients in all
circumstances. Nevertheless, the sensitivities and specifica-
tions of ACEI and AcSDKP are very encouraging.
CONCLUSIONS
Plasma and urine AcSDKP and serum ACE all perform
well with a slight advantage for AcSDKP. Either of these
techniques should now be assessed for its usefulness in
targeting adherence-enhancing strategies toward nonadher-
Table 3. Sensitivity and Specificity of Various Tests and Their Cutoff Values to Differentiate Full Adherence From Full
Nonadherence With ACEI Therapy
Serum
ACE
Plasma
AcSDKP
Urine
AcSDKP AII/AI AI AII
Cutoff 20 U/liter 2 pmol/liter 40 nmol/liter 0.05 110 pmol/liter 5 pmol/liter
Sensitivity, % 86 89 92 89 68 84
Specificity, % 95 100 97 81 76 73
Positive predictive accuracy, % 94 100 97 83 74 76
Negative predictive accuracy, % 88 90 92 88 70 82
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ent patients to see whether such targeted strategies can
improve clinical events.
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